Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

NCT06818721 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

394

Enrollment

OTHER

Sponsor class

Conditions

Retinal Detachment Rhegmatogenous
Proliferative Vitreoretinopathy

Interventions

DRUG: Intravitreal topotecan
PROCEDURE: Retinal detachment surgery

Sponsor

Unity Health Toronto